Estados Unidos · Plataformas y datos · MarketBeat

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

Publicado por MarketBeat · Estados Unidos hace 2 h

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

También te puede interesar

1 Red Flag That Keeps Me From Buying AMD Stock

Yemen’s Houthis renew threat against Riyadh airport as flights set to resume

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Hercules Capital (HTGC) Stock Still Looks Undervalued After A 63% Five Year Run

Bank of America resets Tesla forecast as Robotaxi miles double

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

Compartir

También te puede interesar

1 Red Flag That Keeps Me From Buying AMD Stock

Yemen’s Houthis renew threat against Riyadh airport as flights set to resume

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Hercules Capital (HTGC) Stock Still Looks Undervalued After A 63% Five Year Run

Bank of America resets Tesla forecast as Robotaxi miles double